Viral Genetics Announces Webcast Presentation on August 3, 2011 and Enhancements to Shareholder Communications

Share Article

Viral Genetics, Inc. (Pinksheets: VRAL) will be holding a webcast presentation at 4:30PM Eastern Time on August 3, 2011 to discuss the company’s recent results of operations and other developments in connection with its March 31, 2011 Quarterly Report and 2010 Annual Report.

Viral Genetics, Inc. (Pinksheets: VRAL) will be holding a webcast presentation at 4:30PM Eastern Time on August 3, 2011 to discuss the company’s recent results of operations and other developments in connection with its March 31, 2011 Quarterly Report and 2010 Annual Report. A link to register for the webcast will be provided in a press release prior to the presentation and will also be made available on the Company’s website. Individuals are encouraged to submit questions about the company to info(at)viralgenetics(dot)com for consideration for inclusion in the Q&A session following the presentation by Company President, Haig Keledjian.

The company intends to hold regular webcast presentations to discuss operations moving forward as part of an enhanced overall communications strategy. The timing of any additional presentations may differ from quarterly and annual report filing dates, depending on the pace and timing of new developments.

As part of this effort, the company has also recently added several features to its website at http://www.viralgenetics.com and other communications tools:

  •     Email Signup - Individuals can now provide their name and email address on the company’s website and be provided with press releases, filings, scientific publications, presentation dates, and other information on an ongoing basis.
  •     Corporate Presentation – a PowerPoint presentation is available for download at http://www.viralgenetics.com/VG-IVSTR-Presentation-Q2-11.pptx.zip that discusses the company’s pharmaceutical research programs, its VG Energy subsidiary’s biofuel and agri-tech product development, future milestones, and other company information.
  •     Corporate Fact Sheet – this 1-page summary of the company’s current plans and milestones will be updated at least quarterly, and is also available to download at http://www.viralgenetics.com/ViralGenetics-FactSheet-Q2-11.pdf.

The 2010 and first quarter reports, including unaudited consolidated financial statements for the year ending December 31, 2010 and the three months ended March 31, 2011, are available at http://www.otcmarkets.com/stock/VRAL/financials.

“With so many projects moving forward simultaneously, it is more important than ever to maintain a regular flow of information to our shareholders and stakeholders,” said Viral Genetics’ President, Haig Keledjian.

About Viral Genetics, Inc.
San Marino, California-based Viral Genetics discovers drug therapies from two platform technologies based on over 60 patents: Metabolic Disruption (MDT) and Targeted Peptides (TPT). Founded in 1994, the biotech company is researching treatments for HIV/AIDS, Lyme Disease, Strep, Staph and drug resistant cancer. A majority-owned subsidiary, VG Energy (http://www.vgenergy.net), is dedicated to exploring biofuel and agricultural applications for the MDT platform. For more information, visit http://www.viralgenetics.com.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:
This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports, including statements about its VG Energy, Inc. subsidiary. None of Viral Genetics' drug compounds are approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world, nor are any non-pharmaceutical products of VG Energy, Inc. commercialized. While Viral Genetics believes that the forward-looking statements and underlying assumptions reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of any of its drug therapies in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of those drug compounds in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, the successful outcome of such studies or tests, or the successful commercialization of VG Energy, Inc.’s non-pharmaceutical products. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Haig Keledjian
Viral Genetics, Inc.
(626) 334-5310
Email >
Visit website